Role of Biomarkers for the Management of Crohn’s Disease

Publication Date: November 16, 2023
Last Updated: November 17, 2023

Patients with CD in symptomatic remission

In patients with CD in symptomatic remission, the AGA suggests a monitoring strategy that combines biomarkers and symptoms, rather than relying on symptoms alone. ( Low , Conditional (weak) )
Comment: Patients who place a higher value on avoiding the burden of biomarker testing, over a potentially higher risk of flare and disease progression caused by missing subclinical inflammation, may reasonably choose interval symptom-based monitoring.
612

Patients with symptomatically active CD

In patients with symptomatically active CD, the AGA suggests a biomarker-based assessment and treatment adjustment strategy, rather than relying on symptoms alone. ( Moderate , Conditional (weak) )
Comment: Patients who place a higher value on avoiding the burden of biomarker testing, over a potentially higher risk of over- or undertreatment if relying only on symptoms, may consider choosing interval symptom-based treatment adjustment when being treated for active symptoms.
612

Overview

Title

Role of Biomarkers for the Management of Crohn’s Disease

Authoring Organization